申请人:University College Dublin, National University of Ireland, Dublin
公开号:US11161824B2
公开(公告)日:2021-11-02
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; wherein R2 is an optionally substituted alkoxy or aryloxy group, or with R1 forms a bond; wherein R3 is an optionally substituted alkyl group; and wherein R4 is CH2, CMe2 or O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis.
申请人:University College Dublin,
National University of Ireland, Dublin
公开号:EP3500559B1
公开(公告)日:2021-06-16
HETEROCYCLIC LIPOXON ANALOGS AND USES THEROF
申请人:University College Dublin
公开号:EP3500559A1
公开(公告)日:2019-06-26
Heterocyclic Lipoxin Analogs and Uses Thereof
申请人:University College Dublin
公开号:US20210053927A1
公开(公告)日:2021-02-25
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R
1
is H or with R
2
is a bond; wherein R
2
is an optionally substituted alkoxy or aryloxy group, or with R
1
forms a bond; wherein R
3
is an optionally substituted alkyl group; and wherein R
4
is CH
2
, CMe
2
or O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis.
[EN] HETEROCYCLIC LIPXON ANALOGS AND USES THEROF<br/>[FR] ANALOGUES DE LIPXON HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
申请人:UNIV DUBLIN
公开号:WO2018033642A1
公开(公告)日:2018-02-22
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; wherein R2 is an optionally substituted alkoxy or aryloxy group, or with R1 forms a bond; wherein R3 is an optionally substituted alkyl group; and wherein R4 is CH2, CMe2 or O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis.